This site is intended for Healthcare professionals only.

Metformin may offer protection against macular degeneration risk: JACC Study

Metformin may offer protection against macular degeneration risk: JACC Study

USA: Commonly prescribed antidiabetic drug metformin may offer protection against the development of age-related macular degeneration (AMD), according to a recent study published in the Journal of the American College of Cardiology. 

AMD is the leading cause of irreversible blindness in older individuals in the Western world, and currently, there are no therapies to halt disease progression. AMD includes two forms, dry AMD and wet AMD.

Previous studies have suggested an association between metformin and decreased risk of several ocular diseases. But no study has determined the effect of metformin use on AMD development. Emily E. Brown, Department of Ophthalmology, College of Medicine, University of Florida, Gainesville, Florida, US, and colleagues conducted this retrospective case-control study to investigate whether metformin use is associated with decreased risk of developing AMD.

“To our knowledge, we are the first group to perform an observational study to examine the association of metformin and AMD,” write the authors.

For the purpose, they used medical records from patients older than 55 who visited a University of Florida health clinic between June 2011 and June 2017. They matched three controls for every AMD case to ensure comparable baseline overall health status (1947 AMD patients for 5841 controls).

On analysis, they found that:

  • Further classification determined 505 patients had dry AMD (geographic atrophy) and 115 patients had wet (neovascular) AMD.
  • Among control patients, 10.44% had a history of metformin use while just 4.37% of the AMD patients had a history of taking metformin.
  • Metformin use was associated with decreased odds of developing AMD, independently of the other covariates investigated.
  • Other medications that were examined including dipeptidyl peptidase 4 (DPP4) inhibitors, selective serotonin reuptake inhibitors (SSRI), tetracyclic antidepressants, and statin were not linked to the reduced odds of developing AMD. In fact, some of them were associated with increased odds.
  • A subgroup analysis of this cohort showed that metformin use was associated with decreased odds of developing AMD among patients who had both AMD and diabetes. There were 837 patients who had both, and of those, 84 patients were taking metformin.

“Patients who had taken metformin had decreased odds of developing AMD, suggesting that metformin may have a therapeutic role in AMD development or progression in those who are at risk,” write the authors.

“Further work should include clinical trials to investigate prospectively whether metformin has a protective effect in those at risk for developing AMD.” they concluded.

For complete study follow the link: doi:10.1167/iovs.18-26422

Source: With inputs from Journal of the American College of Cardiology

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted
  1. Metformin inhibits gluconeogenesis. In other words, it puts you on an \”internal\” low glycemic load diet. If I recall, a high glycemic load diet has been associated with AMD.

  2. user
    Cn vishwanath May 26, 2019, 5:34 pm

    Is it more beneficial combination of metformin and statin in every diabetic with or without high cholesterol?. Is it beneficial to treat AMD patients with metformin without diabetes?. In such situation what is the blood glucose level?.

  3. The analysis mention decreased progression of either dry or wet AMD in diabetics who are taking metformin. 40 to 50% people develop diabetes who are on statins and claim the benefits are more. These are all vague messages. What is the effect in patients with AMD treatment with metformin without diabetes. Station reduce stroke rate but long term diabetes affect kidney and retina and these are worse than ctrokes.